US FDA warns Concept Products for failing to fix cGMP violations at Tianjin plant

By Staff Reporter

- Last updated on GMT

iStock/sigurcamp
iStock/sigurcamp

Related tags: Food and drug administration

The US FDA has criticised Chinese manufacturer Concept Products for not fixing cGMP violations observed by inspectors who visited its manufacturing site in Tianjin.

The US regulator criticised Concept in a warning letter​ last week in which it also reiterated violations observed during an inspection of the site - No. 33, The Third Branch Saida Road, Xiqing Economic Development Area, Tianjin – conducted last August.

The agency said although the firm had acknowledged the significance of the current good manufacturing practice (cGMP) violations when it responded last year, it “did not commit to any corrective actions​.”

The violations – which related to product quality and stability testing procedures and the lack of written procedures for production processes and cleaning – earned Concept a Form 483 from the agency last year.

Related topics: Markets & Regulations, QA/QC, Regulations

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Follow us

Products

View more

Webinars